Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells [PDF]
BMC Cardiovascular Disorders, 2005 Background Sirolimus-eluting stents (CYPHER stents) demonstrated remarkable efficacy in reducing restenosis rates in patients with coronary artery disease. There is a concern of sub-acute and late stent thrombosis.
Ming Xiu-Fen +4 more
doaj +5 more sources
Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens [PDF]
Clinical and Translational ScienceDose optimization of sirolimus may further improve outcomes in allogeneic hematopoietic cell transplant (HCT) patients receiving post‐transplantation cyclophosphamide (PTCy) to prevent graft‐versus‐host disease (GVHD).
Ezhilpavai Mohanan +11 more
doaj +2 more sources
A liver transplant patient developed renal injury on tacrolimus and experienced worsening renal function and rhabdomyolysis after switching to sirolimus: a case report. [PDF]
BMC NephrolRenal impairment and rhabdomyolysis are rare in transplant patients receiving sirolimus. We report the case of a 54-year-old male who underwent liver transplantation and was initially treated with tacrolimus, mycophenolate mofetil, and glucocorticoids ...
Gao C, Chen ZY, Ma L, Gou SJ.
europepmc +2 more sources
Case report: Pharmacokinetic interaction involving sirolimus and regorafenib in patients with post-transplant recurrent hepatocellular carcinoma. [PDF]
Front PharmacolBackgroundSirolimus is primarily metabolized by CYP3A4 and transported by P-gp. Drug interactions that affect this pathway can alter its plasma exposures, resulting in untargeted sirolimus concentrations.Case summaryIn this case report, we investigate a ...
Zhu K, Xiong F, Bai H, Liu W.
europepmc +2 more sources
Effect of sirolimus on urinary bladder cancer T24 cell line [PDF]
Journal of Experimental & Clinical Cancer Research, 2009 Background Sirolimus is recently reported to have antitumour effects on a large variety of cancers. The present study was performed to investigate sirolimus's ability to inhibit growth in T24 bladder cancer cells.
Oliveira Paula A +4 more
doaj +7 more sources
Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results [PDF]
Annals of the Child Neurology SocietyObjective Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied in infants.
Jamie K. Capal +19 more
doaj +3 more sources
A Tablet Matrix with Hibiscus rosa Sinensis Leave Mucilage for Effective Treatment of Rare Lymphangioleiomyomatosis Using Sirolimus [PDF]
Trends in Pharmaceutical Sciences, 2022 Using a blend of herbal and synthetic polymers, the authors aim to extend the release of Sirolimus from the tablets. Sirolimus was used as a model drug, Hydroxy Propyl Methyl Cellulose was used as a synthetic polymer, and mucilage from Hibiscus rosa ...
Hindustan Abdul Ahad +5 more
doaj +1 more source
Frontiers in Pharmacology, 2023 The mTOR inhibitor sirolimus is prescribed to treat children with varying diseases, ranging from vascular anomalies to sporadic lymphangioleiomyomatosis to transplantation (solid organ or hematopoietic cell).
Guofang Shen +7 more
doaj +1 more source
Lupus Science and Medicine, 2022 Objective The effectiveness and safety of sirolimus for SLE treatment have been shown in some uncontrolled studies. However, a comparison of sirolimus with other classic immunosuppressants has not been reported.
Xiaofeng Zeng +15 more
doaj +1 more source
Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. [PDF]
PLoS ONE, 2012 The vast majority of glomerular filtrated phosphate is reabsorbed in the proximal tubule. Posttransplant phosphaturia is common and aggravated by sirolimus immunosuppression. The cause of sirolimus induced phosphaturia however remains elusive.
Maria Haller +10 more
doaj +1 more source